Privigen® (immune globulin intravenous [human], 10%) – New indication, new warning
September 14, 2017 – CSL Behring announced the FDA approval of Privigen (immune globulin intravenous [human], 10%) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
Top